This data is derived from company filings and other reputable sources. It has not been generated by AI. It is intended to help verify and validate the AI analysis here. We believe this data to be accurate but we cannot guarentee that it is error free and it should not be relied upon for financial decisions.
| Name | Anavex Life Sciences Corp. |
| Asset Type | EQUITY |
| Industry | Biotechnology |
| Market Capitalization | 720538816 |
| Book Value | 1.169 |
| Eps | -0.56 |
| Analyst Target Price | 34.33333 |
| Forward Pe | -13.396825 |
| Beta | 0.82 |
| Price To Book Ratio | 7.2198453 |
| Share Price | 8.44 |
Annual Financial Statements
Ratios
| 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | |
|---|---|---|---|---|---|
| New Income Growth Rate | -9.48 | -0.99 | 26.56 | N/A | N/A |
| EBITDA Growth Rate | -7.59 | -2.28 | 26.51 | N/A | N/A |
| Free Cash Flow Growth Rate | 10.89 | 14.63 | -20.23 | N/A | N/A |
| Total Asset Growth Rate | -12.19 | 1.10 | -5.51 | N/A | N/A |
| Equity Growt | -15.22 | -0.45 | -5.52 | N/A | N/A |
| Operating Margin | -infT | -infT | -infT | -infT | N/A |
| EBITDA Margin | -infT | -infT | -infT | -infT | N/A |
| EBIT Margin | -infT | -infT | -infT | -infT | N/A |
| Net Profit Margin | -infT | -infT | -infT | -infT | N/A |
| ROE | -0.36 | -0.33 | -0.34 | -0.25 | N/A |
| ROA | -0.32 | -0.31 | -0.31 | -0.23 | N/A |
| Effective Tax Rate | -0.00 | -0.00 | -0.01 | -0.01 | N/A |
| R&D to Revenue | infT | infT | infT | infT | N/A |
| SG&A to Revenue | infT | infT | infT | infT | N/A |
| Current Ratio | 8.86 | 12.32 | 14.95 | 14.97 | N/A |
| Cash Ratio | 8.64 | 12.05 | 14.60 | 14.09 | N/A |
| Cash to Current Assets | 0.98 | 0.98 | 0.98 | 0.94 | N/A |
| Interest Coverage | -infT | -48.27 | -infT | -infT | N/A |
| Liabilities to Equity | 0.13 | 0.09 | 0.07 | 0.07 | N/A |
| Equity Multiplier | 1.13 | 1.09 | 1.07 | 1.07 | N/A |
| ROIC | -0.36 | -0.26 | -0.26 | -0.18 | N/A |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
| Working Capital Turnover | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
| OCF to Sales | -infT | -infT | -infT | -infT | N/A |
| FCF to OCF | 1.00 | 1.00 | 1.00 | 1.00 | N/A |
| Quality of Income | 0.72 | 0.58 | 0.51 | 0.80 | N/A |
| Book Value per Share | 1.42 | 1.73 | 1.83 | 1.99 | N/A |
Income Statement
| 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | -8.4K | -189.8K | -71.8K | N/A |
| Tax Rate For Calcs | 0.00 | 0.21 | 0.21 | 0.27 | N/A |
| Normalized EBITDA | -43.19M | -46.49M | -46.72M | -37.38M | N/A |
| Total Unusual Items | 189.0K | -40.0K | -904.0K | -266.0K | N/A |
| Total Unusual Items Excluding Goodwill | 189.0K | -40.0K | -904.0K | -266.0K | N/A |
| Net Income From Continuing Operation Net Minority Interest | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
| EBITDA | -43.00M | -46.53M | -47.62M | -37.64M | N/A |
| EBIT | -43.00M | -46.53M | -47.62M | -37.64M | N/A |
| Net Interest Income | 7.32M | 5.55M | 947.0K | 26.0K | N/A |
| Interest Expense | 0.00 | 964.0K | 0.00 | 0.00 | N/A |
| Interest Income | 7.32M | 6.52M | 947.0K | 26.0K | N/A |
| Normalized Income | -43.19M | -47.47M | -47.26M | -37.71M | N/A |
| Net Income From Continuing And Discontinued Operation | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
| Total Expenses | 52.80M | 55.73M | 50.99M | 41.95M | N/A |
| Total Operating Income As Reported | -52.88M | -55.76M | -50.99M | -42.00M | N/A |
| Diluted Average Shares | 83.47M | 79.79M | 76.91M | 69.80M | N/A |
| Basic Average Shares | 83.47M | 79.79M | 76.91M | 69.80M | N/A |
| Diluted EPS | -0.52 | -0.60 | -0.62 | -0.54 | N/A |
| Basic EPS | -0.52 | -0.60 | -0.62 | -0.54 | N/A |
| Diluted NI Availto Com Stockholders | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
| Net Income Common Stockholders | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
| Net Income | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
| Net Income Including Noncontrolling Interests | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
| Net Income Continuous Operations | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
| Tax Provision | 0.00 | 7.0K | 358.0K | 268.0K | N/A |
| Pretax Income | -43.00M | -47.50M | -47.62M | -37.64M | N/A |
| Other Income Expense | 2.48M | 2.68M | 2.42M | 4.28M | N/A |
| Other Non Operating Income Expenses | 2.29M | 2.72M | 3.32M | 4.55M | N/A |
| Special Income Charges | N/A | N/A | N/A | N/A | 0.00 |
| Gain On Sale Of Security | 189.0K | -40.0K | -904.0K | -266.0K | N/A |
| Net Non Operating Interest Income Expense | 7.32M | 5.55M | 947.0K | 26.0K | N/A |
| Total Other Finance Cost | N/A | N/A | N/A | N/A | -180.0K |
| Interest Expense Non Operating | 0.00 | 964.0K | 0.00 | 0.00 | N/A |
| Interest Income Non Operating | 7.32M | 6.52M | 947.0K | 26.0K | N/A |
| Operating Income | -52.80M | -55.73M | -50.99M | -41.95M | N/A |
| Operating Expense | 52.80M | 55.73M | 50.99M | 41.95M | N/A |
| Other Operating Expenses | -75.0K | -25.0K | N/A | -54.0K | -149.9K |
| Research And Development | 41.84M | 43.72M | 37.92M | 32.98M | N/A |
| Selling General And Administration | 11.04M | 12.04M | 13.07M | 9.02M | N/A |
| General And Administrative Expense | 11.04M | 12.04M | 13.07M | 9.02M | N/A |
| Other Gand A | 11.04M | 12.04M | 13.07M | 9.02M | N/A |
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
Balance Sheet
| 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | |
|---|---|---|---|---|---|
| Ordinary Shares Number | 84.80M | 82.07M | 77.94M | 75.92M | N/A |
| Share Issued | 84.80M | 82.07M | 77.94M | 75.92M | N/A |
| Tangible Book Value | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Invested Capital | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Working Capital | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Net Tangible Assets | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Common Stock Equity | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Total Capitalization | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Total Equity Gross Minority Interest | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Stockholders Equity | 120.26M | 141.85M | 142.49M | 150.82M | N/A |
| Retained Earnings | -336.07M | -293.07M | -245.56M | -197.59M | N/A |
| Additional Paid In Capital | 456.25M | 434.84M | 387.98M | 348.33M | N/A |
| Capital Stock | 85.0K | 82.0K | 78.0K | 75.9K | N/A |
| Common Stock | 85.0K | 82.0K | 78.0K | 75.9K | N/A |
| Preferred Stock | N/A | N/A | 0.00 | 0.00 | N/A |
| Total Liabilities Net Minority Interest | 15.30M | 12.53M | 10.21M | 10.80M | N/A |
| Total Non Current Liabilities Net Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
| Current Liabilities | 15.30M | 12.53M | 10.21M | 10.80M | N/A |
| Current Deferred Liabilities | 842.0K | 917.0K | 444.0K | 443.8K | N/A |
| Current Deferred Revenue | 842.0K | 917.0K | 444.0K | 443.8K | N/A |
| Pensionand Other Post Retirement Benefit Plans Current | 1.53M | 1.36M | 1.30M | 1.20M | N/A |
| Payables And Accrued Expenses | 12.94M | 10.26M | 8.47M | 9.15M | N/A |
| Current Accrued Expenses | 3.31M | 5.93M | 4.65M | 4.41M | N/A |
| Payables | 9.63M | 4.32M | 3.83M | 4.74M | N/A |
| Accounts Payable | 9.63M | 4.32M | 3.83M | 4.74M | N/A |
| Total Assets | 135.57M | 154.39M | 152.71M | 161.62M | N/A |
| Total Non Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | N/A |
| Current Assets | 135.57M | 154.39M | 152.71M | 161.62M | N/A |
| Other Current Assets | 931.0K | 653.0K | 354.0K | 371.9K | N/A |
| Current Deferred Assets | N/A | N/A | N/A | 16.4K | 0.00 |
| Prepaid Assets | N/A | N/A | 354.2K | 371.9K | 443.8K |
| Receivables | 2.45M | 2.71M | 3.19M | 9.14M | N/A |
| Taxes Receivable | 2.45M | 2.71M | 3.19M | 9.14M | N/A |
| Cash Cash Equivalents And Short Term Investments | 132.19M | 151.02M | 149.16M | 152.11M | N/A |
| Cash And Cash Equivalents | 132.19M | 151.02M | 149.16M | 152.11M | N/A |
Cash Flow Statement
| 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | |
|---|---|---|---|---|---|
| Free Cash Flow | -30.81M | -27.79M | -24.24M | -30.38M | N/A |
| Issuance Of Capital Stock | 11.28M | 27.88M | 20.98M | 153.22M | N/A |
| Income Tax Paid Supplemental Data | 300.0K | 136.0K | 327.0K | 140.0K | N/A |
| End Cash Position | 132.19M | 151.02M | 149.16M | 152.11M | N/A |
| Beginning Cash Position | 151.02M | 149.16M | 152.11M | 29.25M | N/A |
| Changes In Cash | -18.84M | 1.87M | -2.95M | 122.86M | N/A |
| Financing Cash Flow | 11.97M | 29.65M | 21.29M | 153.24M | N/A |
| Cash Flow From Continuing Financing Activities | 11.97M | 29.65M | 21.29M | 153.24M | N/A |
| Net Other Financing Charges | N/A | N/A | -707.0K | -5.55M | -403.8K |
| Proceeds From Stock Option Exercised | 691.0K | 1.78M | 1.01M | 5.58M | N/A |
| Net Common Stock Issuance | 11.28M | 27.88M | 20.98M | 153.22M | N/A |
| Common Stock Issuance | 11.28M | 27.88M | 20.98M | 153.22M | N/A |
| Operating Cash Flow | -30.81M | -27.79M | -24.24M | -30.38M | N/A |
| Cash Flow From Continuing Operating Activities | -30.81M | -27.79M | -24.24M | -30.38M | N/A |
| Change In Working Capital | 2.75M | 2.50M | 5.36M | -706.0K | N/A |
| Change In Other Working Capital | -75.0K | 473.0K | N/A | 444.0K | N/A |
| Change In Payables And Accrued Expense | 2.85M | 1.85M | -584.0K | 3.05M | N/A |
| Change In Accrued Expense | -2.46M | 1.35M | 330.0K | 2.30M | N/A |
| Change In Payable | 5.30M | 497.0K | -914.0K | 751.0K | N/A |
| Change In Account Payable | 5.30M | 497.0K | -914.0K | 751.0K | N/A |
| Change In Prepaid Assets | -278.0K | -299.0K | 1.0K | 88.0K | N/A |
| Change In Receivables | 260.0K | 484.0K | 5.94M | -4.29M | N/A |
| Other Non Cash Items | N/A | 845.0K | N/A | N/A | N/A |
| Stock Based Compensation | 9.44M | 16.37M | 18.38M | 8.23M | N/A |
| Net Income From Continuing Operations | -43.00M | -47.51M | -47.98M | -37.91M | N/A |
Quarterly Financial Statements
Ratios
| 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | |
|---|---|---|---|---|---|
| New Income Growth Rate | -7.56 | 4.23 | -4.86 | 15.82 | N/A |
| EBITDA Growth Rate | -8.56 | 15.63 | -4.37 | 1.06 | N/A |
| Free Cash Flow Growth Rate | -51.68 | 82.04 | 28.53 | -55.56 | N/A |
| Total Asset Growth Rate | -5.57 | -8.50 | -4.22 | -2.06 | N/A |
| Equity Growt | -10.06 | -7.77 | -7.33 | -3.84 | N/A |
| Operating Margin | -infT | -infT | -infT | -infT | -infT |
| EBITDA Margin | -infT | -infT | -infT | -infT | -infT |
| EBIT Margin | -infT | -infT | -infT | -infT | -infT |
| Net Profit Margin | -infT | -infT | -infT | -infT | -infT |
| ROE | -0.11 | -0.11 | -0.10 | -0.09 | -0.08 |
| ROA | -0.10 | -0.10 | -0.09 | -0.09 | -0.07 |
| Effective Tax Rate | N/A | N/A | 0.01 | 0.01 | -0.01 |
| R&D to Revenue | infT | infT | infT | infT | infT |
| SG&A to Revenue | infT | infT | infT | infT | infT |
| Current Ratio | 6.74 | 9.45 | 8.86 | 12.04 | 15.12 |
| Cash Ratio | 6.66 | 9.20 | 8.64 | 11.81 | 14.58 |
| Cash to Current Assets | 0.99 | 0.97 | 0.98 | 0.98 | 0.96 |
| Interest Coverage | N/A | N/A | -infT | -infT | -infT |
| Liabilities to Equity | 0.17 | 0.12 | 0.13 | 0.09 | 0.07 |
| Equity Multiplier | 1.17 | 1.12 | 1.13 | 1.09 | 1.07 |
| ROIC | -0.12 | -0.12 | -0.10 | -0.09 | -0.09 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| OCF to Sales | -infT | -infT | -infT | -infT | -infT |
| FCF to OCF | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Quality of Income | 0.52 | 1.00 | 0.57 | 0.42 | 1.11 |
| Book Value per Share | 1.17 | 1.31 | 1.42 | 1.53 | 1.61 |
Income Statement
| 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 1.2K | 365.52 | 0.00 |
| Tax Rate For Calcs | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Normalized EBITDA | -12.43M | -13.24M | -11.86M | -12.35M | -12.00M |
| Total Unusual Items | 11.0K | -337.0K | 117.0K | 67.0K | -150.0K |
| Total Unusual Items Excluding Goodwill | 11.0K | -337.0K | 117.0K | 67.0K | -150.0K |
| Net Income From Continuing Operation Net Minority Interest | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
| EBITDA | -12.42M | -13.58M | -11.74M | -12.28M | -12.15M |
| EBIT | -12.42M | -13.58M | -11.74M | -12.28M | -12.15M |
| Net Interest Income | 1.21M | 1.39M | 1.76M | 1.80M | 1.76M |
| Interest Expense | N/A | N/A | 0.00 | 0.00 | 0.00 |
| Interest Income | 1.21M | 1.39M | 1.76M | 1.80M | 1.76M |
| Normalized Income | -11.21M | -11.77M | -11.74M | -12.28M | -10.40M |
| Net Income From Continuing And Discontinued Operation | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
| Total Expenses | 12.42M | 13.58M | 14.26M | 14.73M | 12.15M |
| Total Operating Income As Reported | -12.51M | -13.59M | -14.34M | -14.73M | -12.62M |
| Diluted Average Shares | 85.07M | 84.81M | N/A | 84.54M | 82.46M |
| Basic Average Shares | 85.07M | 84.81M | N/A | 84.54M | 82.46M |
| Diluted EPS | -0.13 | -0.14 | N/A | -0.14 | -0.13 |
| Basic EPS | -0.13 | -0.14 | N/A | -0.14 | -0.13 |
| Diluted NI Availto Com Stockholders | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
| Net Income Common Stockholders | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
| Net Income | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
| Net Income Including Noncontrolling Interests | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
| Net Income Continuous Operations | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
| Tax Provision | N/A | N/A | -124.0K | -67.0K | 105.0K |
| Pretax Income | -11.20M | -12.11M | -11.74M | -12.28M | -10.55M |
| Other Income Expense | 11.0K | 75.0K | 758.0K | 652.0K | -150.0K |
| Other Non Operating Income Expenses | N/A | 412.0K | 641.0K | 585.0K | N/A |
| Gain On Sale Of Security | 11.0K | -337.0K | 117.0K | 67.0K | -150.0K |
| Net Non Operating Interest Income Expense | 1.21M | 1.39M | 1.76M | 1.80M | 1.76M |
| Interest Expense Non Operating | N/A | N/A | 0.00 | 0.00 | 0.00 |
| Interest Income Non Operating | 1.21M | 1.39M | 1.76M | 1.80M | 1.76M |
| Operating Income | -12.42M | -13.58M | -14.26M | -14.73M | -12.15M |
| Operating Expense | 12.42M | 13.58M | 14.26M | 14.73M | 12.15M |
| Other Operating Expenses | -96.0K | -12.0K | N/A | N/A | -472.0K |
| Research And Development | 9.89M | 10.45M | 11.55M | 11.87M | 9.73M |
| Selling General And Administration | 2.62M | 3.15M | 2.78M | 2.86M | 2.90M |
| General And Administrative Expense | 2.62M | 3.15M | 2.78M | 2.86M | 2.90M |
| Other Gand A | 2.62M | 3.15M | 2.78M | 2.86M | 2.90M |
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
| 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | |
|---|---|---|---|---|---|
| Treasury Shares Number | N/A | N/A | N/A | N/A | N/A |
| Ordinary Shares Number | 85.33M | 84.99M | 84.80M | 84.80M | 83.62M |
| Share Issued | 85.33M | 84.99M | 84.80M | 84.80M | 83.62M |
| Tangible Book Value | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Invested Capital | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Working Capital | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Net Tangible Assets | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Common Stock Equity | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Total Capitalization | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Total Equity Gross Minority Interest | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Stockholders Equity | 99.76M | 110.92M | 120.26M | 129.78M | 134.96M |
| Other Equity Interest | N/A | N/A | N/A | -89.0K | -234.0K |
| Retained Earnings | -359.38M | -348.18M | -336.07M | -324.45M | -312.24M |
| Additional Paid In Capital | 459.05M | 459.01M | 456.25M | 454.24M | 447.35M |
| Capital Stock | 85.0K | 85.0K | 85.0K | 85.0K | 84.0K |
| Common Stock | 85.0K | 85.0K | 85.0K | 85.0K | 84.0K |
| Preferred Stock | 0.00 | N/A | N/A | N/A | N/A |
| Total Liabilities Net Minority Interest | 17.38M | 13.13M | 15.30M | 11.75M | 9.56M |
| Total Non Current Liabilities Net Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Liabilities | 17.38M | 13.13M | 15.30M | 11.75M | 9.56M |
| Current Deferred Liabilities | 829.0K | 829.0K | 842.0K | 917.0K | 917.0K |
| Current Deferred Revenue | 829.0K | 829.0K | 842.0K | 917.0K | 917.0K |
| Pensionand Other Post Retirement Benefit Plans Current | 2.20M | 2.02M | 1.53M | 1.03M | 630.0K |
| Payables And Accrued Expenses | 14.35M | 10.28M | 12.94M | 9.81M | 8.01M |
| Current Accrued Expenses | 7.36M | 5.71M | 3.31M | 6.30M | 4.29M |
| Payables | 7.00M | 4.57M | 9.63M | 3.50M | 3.73M |
| Accounts Payable | 7.00M | 4.57M | 9.63M | 3.50M | 3.73M |
| Total Assets | 117.14M | 124.04M | 135.57M | 141.53M | 144.52M |
| Total Non Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Assets | 117.14M | 124.04M | 135.57M | 141.53M | 144.52M |
| Other Current Assets | 702.0K | 711.0K | 931.0K | 1.06M | 1.34M |
| Receivables | 666.0K | 2.56M | 2.45M | 1.72M | 3.79M |
| Taxes Receivable | 666.0K | 2.56M | 2.45M | 1.72M | 3.79M |
| Cash Cash Equivalents And Short Term Investments | 115.77M | 120.78M | 132.19M | 138.76M | 139.39M |
| Cash And Cash Equivalents | 115.77M | 120.78M | 132.19M | 138.76M | 139.39M |
Cash Flow Statement
| 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | -5.86M | -12.12M | -6.66M | -5.18M | -11.66M |
| Issuance Of Capital Stock | N/A | N/A | 0.00 | 4.11M | N/A |
| Income Tax Paid Supplemental Data | -7.0K | 43.0K | 80.0K | 0.00 | 173.0K |
| End Cash Position | 115.77M | 120.78M | 132.19M | 138.76M | 139.39M |
| Beginning Cash Position | 120.78M | 132.19M | 138.76M | 139.39M | 143.76M |
| Changes In Cash | -5.00M | -11.41M | -6.57M | -630.0K | -4.38M |
| Financing Cash Flow | 852.0K | 708.0K | 89.0K | 4.55M | 7.28M |
| Cash Flow From Continuing Financing Activities | 852.0K | 708.0K | 89.0K | 4.55M | 7.28M |
| Proceeds From Stock Option Exercised | 852.0K | 708.0K | 89.0K | 444.0K | 99.0K |
| Net Common Stock Issuance | N/A | N/A | 0.00 | 4.11M | N/A |
| Common Stock Issuance | N/A | N/A | 0.00 | 4.11M | N/A |
| Operating Cash Flow | -5.86M | -12.12M | -6.66M | -5.18M | -11.66M |
| Cash Flow From Continuing Operating Activities | -5.86M | -12.12M | -6.66M | -5.18M | -11.66M |
| Change In Working Capital | 3.89M | -2.06M | 2.89M | 4.61M | -3.76M |
| Change In Other Working Capital | 1.0K | -13.0K | N/A | N/A | N/A |
| Change In Payables And Accrued Expense | 1.99M | -2.16M | 3.57M | 2.25M | -2.94M |
| Change In Accrued Expense | 1.82M | 2.90M | -2.50M | 2.42M | -2.37M |
| Change In Payable | 167.0K | -5.06M | 6.07M | -164.0K | -566.0K |
| Change In Account Payable | 167.0K | -5.06M | 6.07M | -164.0K | -566.0K |
| Change In Prepaid Assets | 9.0K | 220.0K | 128.0K | 286.0K | -589.0K |
| Change In Receivables | 1.89M | -108.0K | -729.0K | 2.06M | -236.0K |
| Other Non Cash Items | N/A | N/A | N/A | N/A | N/A |
| Stock Based Compensation | 1.45M | 2.06M | 2.01M | 2.49M | 2.65M |
| Net Income From Continuing Operations | -11.20M | -12.11M | -11.62M | -12.21M | -10.55M |
Legal Disclaimer
The information contained on this website and associated documents, including all text, data, analyses, opinions, and forward-looking statements, is provided solely for general informational purposes and does not constitute financial, investment, legal, or tax advice. The content has been generated by an artificial intelligence tool using publicly available data and company filings. Although every effort has been made to ensure accuracy, the information is provided “as is” without any warranty—express or implied—of completeness, accuracy, reliability, or suitability for any purpose.
Not Regulated Advice
No FCA Authorization: We are not authorized or regulated by the Financial Conduct Authority (FCA) or any other financial regulatory body to offer investment advice or recommendations. Nothing in this report should be construed as a solicitation, recommendation, or endorsement to buy, sell, or hold any security or financial instrument.
Independent Decision-Making: Investors are strongly encouraged to conduct their own research and consult with a licensed financial advisor or other professional before making any financial decisions. Reliance on the information provided herein is solely at your own risk.
Forward-Looking Statements
This report may contain forward-looking statements, which are based on current expectations, assumptions, and projections that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. We do not undertake any obligation to update or revise any forward-looking statements in light of new information or future developments.
Limitation of Liability
Under no circumstances shall Aipha.io or its affiliates, employees, or agents be liable for any direct, indirect, incidental, consequential, or other damages arising out of or in connection with the use of, or reliance on, the information contained in this report—even if advised of the possibility of such damages. This includes, without limitation, any loss of profit, revenue, or data.
Use at Your Own Risk
By using this report, you acknowledge that you have read and understood this disclaimer and agree that any reliance on the information provided is at your own risk. [Your Company Name/Aipha.io] expressly disclaims any and all liability for any loss or damage of any kind incurred as a result of any use of this report.